Rituximab-associated progressive multifocal leukoencephalopathy.

Area of Science:

• Neurology
• Immunology
• Virology

Background:

• Progressive Multifocal Leukoencephalopathy (PML) is a fatal demyelinating disease of the central nervous system (CNS).
• PML is caused by the John Cunningham virus (JCV), first isolated in 1971.
• It primarily affects immunocompromised individuals, often those with lymphoproliferative disorders.

Observation:

• A rare case of PML in a 62-year-old male with chronic lymphocytic leukemia (CLL) is presented.
• The case highlights the diagnostic and therapeutic complexities associated with PML in this patient population.
• Neurological symptoms in patients on monoclonal antibody therapy warrant a high index of suspicion for PML.

Findings:

• Regular monitoring of immunoglobulin levels and CD4+:CD8+ T-cell ratio is recommended.
• Intravenous immunoglobulin administration may be considered for reduced immunoglobulin levels.
• Careful risk-benefit assessment is necessary when continuing monoclonal antibody treatment if immunoglobulin levels cannot be restored.

Implications:

• Physicians should maintain vigilance for PML development in patients receiving monoclonal antibody treatments.
• Proactive immune monitoring can aid in the early detection and management of PML.
• Understanding PML pathogenesis and risk factors is vital for preventing its occurrence in susceptible patients.